Kiora Pharmaceuticals announces $15M private placement with potential $30M from warrant exercises

KIORA PHARMACEUTICALS INC

Upfront gross proceeds of $15M from sale of shares and pre-funded warrants at $0.5524 per unit.
Tranche A warrants (24.7M shares, $0.6076 exercise) tied to KIO-301 Phase 2 data; Tranche B tied to KIO-104 Phase 2.
Participating investors include ADAR1 Capital, Nantahala Capital, Rosalind Advisors, Stonepine Capital, Velan Capital.
Net proceeds to fund KIO-104 development for posterior non-infectious uveitis and general operations.
Closing expected on or about February 5, 2024, subject to customary conditions.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

KIORA PHARMACEUTICALS INC entered into Securities Purchase Agreement with certain institutional investors valued at approximately $15.0 million (effective 2024-01-31).

Action: entry
Agreement: equity purchase
Counterparty: certain institutional investors
Value: approximately $15.0 million
Effective: 2024-01-31

Exact text from the filing

On January 31, 2024, Kiora Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors (the “Purchasers”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

KIORA PHARMACEUTICALS INC entered into Placement Agency Agreement with Maxim Group LLC (effective 2024-01-31).

Action: entry
Agreement: underwriting
Counterparty: Maxim Group LLC
Effective: 2024-01-31

Exact text from the filing

On January 31, 2024 and in connection with the Securities Purchase Agreement, the Company entered into a customary placement agency agreement (the “Placement Agency Agreement”) with Maxim Group LLC (“Maxim”).

View on SEC.gov

Browse all material agreements →

KIORA PHARMACEUTICALS INC filing history →

Source: SEC EDGAR

accession 0001372514-24-000010

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.